Wealthion’s Best Of 2025: Chris Casey — Cannabis Stocks Down 90% — The Ultimate Contrarian Bet?

Cannabis Industry: A Contrarian Investment Opportunity

Key Concepts:

• Contrarian Investing: Identifying mispriced assets in the market and capitalizing on catalysts that will correct the mispricing.
• Rescheduling: Altering the federal classification of cannabis, potentially impacting tax burdens and legal restrictions.
• SAFER Act: Proposed legislation granting banking protections to cannabis businesses.
• Section 280E (IRS Code): A tax code provision that prevents cannabis companies from deducting typical business expenses.
• Call Option: Viewing heavily discounted assets as options on future growth, particularly in a high-growth industry.
• Schedule I Drug: The most restrictive classification under the Controlled Substances Act, currently applied to cannabis federally.

I. Historical Context & Current Landscape

Cannabis has a complex legal history in the US. Initially prohibited in the 1920s and effectively illegalized by the 1937 Marijuana Tax Act, it was further classified as a Schedule I drug in the 1970s – a designation reserved for substances with no accepted medical value and high addiction potential. However, since 1996, with California’s medicinal legalization, a wave of state-level legalization has occurred. Currently, approximately 40 states have legalized cannabis in some form (medicinal or recreational), with around 24 allowing recreational use. This means roughly 75% of the US population has access to recreational cannabis and over 50% to medicinal. Despite this state-level progress, cannabis remains illegal at the federal level, creating significant operational challenges for businesses.

II. Market Size & Growth Potential

The US cannabis market is currently valued at approximately $30 billion in sales annually, compared to $5 billion in Canada (adjusted for population, equivalent to $40 billion). This is significantly smaller than the alcohol ($100+ billion) and tobacco ($85 billion) industries, indicating substantial growth potential. Forecasts predict sales reaching $35-45 billion by 2025. The growth is fueled by increasing social acceptance, with even traditionally conservative demographics exploring cannabis for medicinal purposes.

III. Challenges Facing the Cannabis Industry

Despite the growth potential, the cannabis industry faces three key impediments:

1. Burdensome Tax Regime (Section 280E): Cannabis companies are restricted from deducting standard business expenses (payroll, rent, utilities) under Section 280E of the IRS code, resulting in extremely high effective tax rates based on gross margins.
2. Interstate Commerce Restrictions: Federal prohibition prevents cannabis businesses from operating across state lines, hindering efficiency and scalability. The current system is inefficient, with localized production and distribution. Allowing interstate commerce could lead to lower-cost production in states like Kentucky and Virginia, and the development of online distribution networks.
3. Limited Access to Capital: Due to federal illegality, cannabis companies struggle to access traditional banking services and capital markets. Debt financing, when available, often comes with high interest rates (10%+) and restrictive covenants. Even real estate companies with cannabis tenants face difficulty securing financing.

IV. Potential Catalysts for Change

Two primary catalysts could reverse the fortunes of cannabis companies:

1. Rescheduling: The Biden administration initiated a review of cannabis scheduling in October 2022, but the process has stalled. Rescheduling, ideally to a lower classification than Schedule I, would alleviate tax burdens and potentially ease banking restrictions. However, simply moving it to Schedule II or III wouldn’t fully address the issues.
2. The SAFER Act: This proposed legislation would provide banking protections for cannabis businesses, allowing financial institutions to serve the industry without fear of federal repercussions. The SAFER Act has passed through committee but awaits a floor vote.

V. Investment Considerations & Current Valuation

The cannabis sector has experienced a significant downturn, with stocks down 80-90% from their highs, and 70-80% in the last 12 months. This presents a potential opportunity for contrarian investors. Current valuations, while still challenged by negative cash flow, are becoming more reasonable:

• Price-to-Sales Ratio: Generally below 1x.
• Gross Profit Margin: Companies maintain profitability at the gross profit margin level.
• Liquidity: Not significantly impaired.

However, investors should focus on well-capitalized, market-leading companies with strong branding, as consolidation is likely to occur once regulatory hurdles are cleared. The potential upside is substantial – stocks could potentially increase 2-6x if they return to their 52-week highs.

VI. Consolidation & Future Landscape

The implementation of the SAFER Act or rescheduling is expected to trigger significant consolidation within the cannabis industry. Larger, established companies will likely acquire smaller players, leveraging improved access to capital and market share. Furthermore, established industries like tobacco and beverages are expected to enter the cannabis market, potentially driving further innovation and competition. The shift towards widespread acceptance will also likely lead to increased use of cannabis-derived products for medicinal purposes, including transdermal applications.

VII. Investor Exposure & Accessibility

Currently, investor exposure to the cannabis sector is relatively low. Many registered investment advisors avoid the space, and some custodians restrict their clients from purchasing cannabis stocks. This limited accessibility contributes to the undervaluation of the sector.

Notable Quote:

“Whenever something’s beat up this much, 90 plus%, I view it as a call option. It’s a call option on a high growth industry for distress companies. And I can’t think of a better place to be.” – Chris Casey, Windrock Wealth Management.

Conclusion:

The cannabis industry remains a high-risk, high-reward investment opportunity. While significant challenges persist due to federal prohibition, potential catalysts like rescheduling and the SAFER Act could unlock substantial value. The current depressed valuations, coupled with the industry’s growth potential, make it an attractive option for contrarian investors willing to take a long-term perspective. However, careful due diligence and a focus on well-positioned companies are crucial for success.